Mantzourani, Efthymia D. ![]() |
Abstract
Peptides regulate most physiological processes, mainly by binding to specific receptors located on the cell surface and inducing a series of signals, neurotransmissions or the release of growth factors. There has been a rapid expansion in the use of peptides as therapeutic agents after the 1960s, but a series of unfortunate side effects present in Phase I and II clinical studies combined with their low bioavailability, led to the introduction of the idea of peptidomimetics as alternative compounds that mimic the biological activity of peptides, while offering the advantages of increased bioavailability, biostability, bioefficiency, and bioselectivity. Since then new peptides with promising in vitro results, involving the monoclonal antibody expansion, as well as the newly launched research field for novel formulations for increasing peptides' bioavailability, redirected the interest on the peptide market. In this report we will highlight three areas where the use of peptides has shown promising results, with products that are either currently used as drugs or included into Phase III clinical studies.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Pharmacy |
Subjects: | R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica |
Uncontrolled Keywords: | Peptides; altered peptide ligands (APLs); cyclic peptide; hypertension; angiotensin; gonadotropin releasing Hormone (GnRH); multiple sclerosis (MS); immunotherapy |
Publisher: | Bentham Science Publishers |
ISSN: | 1871-5230 |
Last Modified: | 19 Oct 2022 08:31 |
URI: | https://orca.cardiff.ac.uk/id/eprint/18091 |
Citation Data
Cited 14 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |